title: Integrated genomic analysis identifies subclasses and prognosis signatures of kidney cancer.
abstract: OBJECTIVE
  To define robust miRNA-based molecular classifiers for human clear cell renal cell carcinoma (ccRCC) subgrouping and prognostication.
  
  
  METHODS
  Multidimensional data of over 500 clear cell renal cell carcinoma (ccRCC) patients were retrieved from The Cancer Genome Atlas (TCGA) archive. Data analysis was based on a novel computational approach that selectively considers patients with extreme expression values of miRNAs to detect survival-associated molecular signatures.
  
  
  RESULTS
  Our in silico analysis unveiled a novel ccRCC-specific 5-miRNA (miR-10b, miR-21, miR-143, miR-183, and miR-192) signature able, when combined with information from conventional TNM staging and the age of the patient, to prognosticate ccRCC outcome more accurately than known ccRCC miRNA signatures or TNM staging alone. Furthermore, our approach revealed the existence of 6 distinct subgroups of ccRCC characterized by discrete differences in overall survival, tumor stage, and mutational spectra in key ccRCC tumor suppressor genes. It also demonstrated that BAP1 mutations correlate with tumor progression rather than overall survival.
  
  
  CONCLUSIONS
  Integrated analysis of multidimensional data from the TCGA archive allowed to draw a portrait of distinct molecular subclasses of human ccRCC and to define signatures for prognosticating disease outcome. Together, these results offer new prospects for more accurate stratification and prognostication of ccRCC.
authors.affiliation: Institute of Molecular Health Sciences, ETH Zurich, 8093 Zurich, Switzerland.
authors.forename: Yann
authors.initials: Y
authors.lastname: Christinat
authors.affiliation: Institute of Molecular Health Sciences, ETH Zurich, 8093 Zurich, Switzerland.
authors.forename: Wilhelm
authors.initials: W
authors.lastname: Krek
mesh_terms: D002292:Carcinoma, Renal Cell / Q000145:classification / Q000235:genetics* / Q000473:pathology; D015331:Cohort Studies; D020869:Gene Expression Profiling; D023281:Genomics / Q000379:methods; D006801:Humans; D007680:Kidney Neoplasms / Q000145:classification / Q000235:genetics* / Q000473:pathology; D035683:MicroRNAs / Q000032:analysis / Q000235:genetics*; D009154:Mutation; D011379:Prognosis; D016019:Survival Analysis; D025521:Tumor Suppressor Proteins / Q000235:genetics; D043222:Ubiquitin Thiolesterase / Q000235:genetics
chemical_list: C400134:BAP1 protein, human; D035683:MicroRNAs; D025521:Tumor Suppressor Proteins; D043222:Ubiquitin Thiolesterase
keywords: TCGA; cancer; clear-cell renal cell carcinoma; miRNA; prognosis
references.citation: Diabetes. 2013 Sep;62(9):3151-62
references.pmid: 23649518
references.citation: Eur Urol. 2014 Jul;66(1):77-84
references.pmid: 24613583
references.citation: Cancer Biol Ther. 2014 Mar 1;15(3):329-41
references.pmid: 24351440
references.citation: J Biomed Inform. 2011 Oct;44(5):839-47
references.pmid: 21605702
references.citation: Eur J Cell Biol. 1999 Nov;78(11):767-78
references.pmid: 10604653
references.citation: PLoS One. 2012;7(5):e35661
references.pmid: 22623952
references.citation: BMC Bioinformatics. 2010 Jul 02;11:367
references.pmid: 20598126
references.citation: Am J Cancer Res. 2012;2(4):414-33
references.pmid: 22860232
references.citation: Nat Genet. 2013 Aug;45(8):860-7
references.pmid: 23797736
references.citation: Nature. 2013 Jul 4;499(7456):43-9
references.pmid: 23792563
references.citation: Ann Surg Oncol. 2010 Jun;17(6):1471-4
references.pmid: 20180029
references.citation: Cancer. 2006 Dec 1;107(11):2523-4
references.pmid: 17075870
references.citation: Cancer. 2013 Feb 15;119(4):814-24
references.pmid: 22990979
references.citation: World J Urol. 2011 Jun;29(3):367-73
references.pmid: 21229250
references.citation: Int J Mol Med. 2013 Jun;31(6):1436-42
references.pmid: 23588932
references.citation: Clin Chim Acta. 2013 Feb 1;416:5-10
references.pmid: 23178446
references.citation: J Transl Med. 2013 Jul 10;11:169
references.pmid: 23841900
references.citation: Int J Oncol. 2009 Jul;35(1):109-14
references.pmid: 19513557
references.citation: Brief Bioinform. 2013 Nov;14(6):671-83
references.pmid: 22988256
references.citation: Nat Genet. 2014 Mar;46(3):225-233
references.pmid: 24487277
references.citation: Eur Urol. 2010 Jan;57(1):102-9
references.pmid: 19062157
references.citation: RNA. 2008 Aug;14(8):1480-91
references.pmid: 18579870
references.citation: Hepatology. 2012 Jan;55(1):98-107
references.pmid: 21887698
references.citation: J Natl Cancer Inst. 2005 Aug 17;97(16):1180-4
references.pmid: 16106022
references.citation: Sci Transl Med. 2013 Apr 17;5(181):181re1
references.pmid: 23596205
references.citation: Gynecol Oncol. 2011 Jun 1;121(3):444-50
references.pmid: 21354599
references.citation: J Nanosci Nanotechnol. 2013 May;13(5):3195-203
references.pmid: 23858831
references.citation: Mol Oncol. 2012 Aug;6(4):445-57
references.pmid: 22552153
references.citation: Stat Med. 1996 Feb 28;15(4):361-87
references.pmid: 8668867
references.citation: Genes Chromosomes Cancer. 2012 Jul;51(7):707-16
references.pmid: 22492545
references.citation: Eur J Cancer. 2014 Jul;50(10):1758-1765
references.pmid: 24793999
references.citation: Carcinogenesis. 2013 Oct;34(10):2231-9
references.pmid: 23715501
references.citation: Cancer J. 2013 Jul-Aug;19(4):324-32
references.pmid: 23867514
references.citation: Urol Oncol. 2012 Nov-Dec;30(6):948-51
references.pmid: 23218074
references.citation: Biochim Biophys Acta. 2013 Dec;1832(12):2352-67
references.pmid: 24075941
references.citation: Biom J. 2011 Mar;53(2):170-89
references.pmid: 21328602